Evotec SE

EVT

DE0005664809

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 08:24:13 2024-04-23 am EDT			5-day change	1st Jan Change
14.1 ^EUR	+2.92%		+6.65%	-33.69%

Apr. 18	Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis	MT
Apr. 18	Evotec, Variant Bio Launch Partnership to Develop Treatments for Fibrosis	MT

EVOTEC : Receives a Buy rating from Warburg Research

August 12, 2022 at 06:58 am EDT

Already positive, the research from Warburg Research and its analyst Christian Ehmann still consider the stock as a Buy opportunity. The target price is lowered from EUR 38 to EUR 34.

Latest news about Evotec SE

Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis	Apr. 18	MT
Evotec, Variant Bio Launch Partnership to Develop Treatments for Fibrosis	Apr. 18	MT
Evotec Names First Chief People Officer	Apr. 17	MT
Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024	Apr. 17	CI
Deutsche Bank raises Evotec to 'Buy' - Frustration after CEO departure overcome	Apr. 12	DP
STOXX 600 climbs over 1% on rate-cut optimism	Apr. 12	RE
Deutsche Bank Research raises Evotec to 'Buy' - Target 19 Euro	Apr. 12	DP
EVOTEC : Deutsche Bank takes a positive view	Apr. 12	ZD
U.S. Futures, European Stocks Up as ECB Signals Moving Closer to Rate Cut	Apr. 12	DJ
EVOTEC : Receives a Buy rating from Jefferies	Mar. 28	ZD
Aeovian Pharmaceuticals, Inc. announced that it has received $87 million in funding from Sofinnova Investment, Inc., Evotec SE, venBio LLC, Apollo Health Ventures, b2venture AG, Hevolution Foundation	Mar. 27	CI
Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Hevolution Foundation, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG	Mar. 27	CI
Tubulis Technologies announced that it has received ?128 million in funding from a group of investors	Mar. 13	CI
Evotec Grants Claris Ventures Portfolio Biotech Firms Access to Testing Platform	Mar. 06	MT
EVOTEC : Warburg Research maintains a Buy rating	Mar. 05	ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading	Feb. 07	MT
Evotec Unit, Advanced BioScience Expand Agreement to Develop Antibodies Against HIV	Feb. 07	MT
Evotec's US Unit Expands Collaboration vs HIV with Advanced BioScience Laboratories	Feb. 07	MT
EVOTEC : RBC remains its Buy rating	Jan. 26	ZD
Jefferies lowers target for Evotec to 28 Euro - 'Buy'	Jan. 26	DP
EVOTEC : Jefferies remains its Buy rating	Jan. 26	ZD
Global markets live: Crest Nicholson, Gilead, United Airlines, 3M Company, General Electric...	Jan. 23
EVOTEC : RBC gives a Buy rating	Jan. 23	ZD
Evotec Says Former CEO Failed to Disclose Stock Trades Over 3 Years	Jan. 22	MT
Evotec Reiterates Trading Regulations Compliance Amid Former CEO’s Late Stock Trades Disclosure	Jan. 22	MT

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-04-23 - Q4 2023 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.7 EUR

Average target price

25.4 EUR

Spread / Average Target

+85.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-33.69%	2.59B
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+48.37%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research

Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

EVOTEC : Receives a Buy rating from Warburg Research

Latest news about Evotec SE

Chart Evotec SE

Company Profile

Income Statement Evolution

Ratings for Evotec SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research